甘木通总黄酮对表柔比星心肌毒性的抑制作用及机制研究
|
摘要
目的:研究甘木通总黄酮对表柔比星心肌毒性的抑制作用及机制。方法:从初生SD大鼠分离培养原代心肌细胞,以1.0μmol/L表柔比星建立心肌毒性模型,采用表面活性剂-超声协同方法提取甘木通中总黄酮,设3个药物浓度组,在损伤模型的基础上分别加入终浓度为25、50、100μg/m L的甘木通总黄酮,阳性对照组加入10μmol/L右丙亚胺,各组均作用24 h,采用CCK-8检测细胞存活率,Hoechst33258染色观察细胞的凋亡形态,JC-1荧光探针检测线粒体膜电位变化,Western blot检测凋亡相关信号蛋白Bax、Bcl-2及cleaved Caspase-3的表达量,采用比色法测定超氧化物歧化酶(SOD)活性以及丙二醛(MDA)的生成量。结果:与模型组比较,甘木通总黄酮各剂量均可显著提高心肌细胞的存活率,降低表柔比星对线粒体的损伤,并可通过降低Bax及上调Bcl-2的表达量抑制cleaved Caspase-3的生成,进而抑制细胞的凋亡(P<0.05);同时能提高SOD的活性,抑制脂质过氧化反应从而降低MDA的生成(P<0.05)。结论:甘木通总黄酮可通过抑制脂质过氧化反应干预细胞凋亡的线粒体通路从而降低表柔比星的心肌毒性。
Objective: To study the protective effect and mechanism of total flavones of Clematis filamentosa( TFC) mitigating cardiotoxicity which induced by epirubicin( Epi). Methods: The myocardial cells separated from neonate SD rats was induced to apoptosis with 1. 0 μmol/L epirubicin to establish cardiotoxicity model. Three experimental groups were treated with 25,50,100 μg/m L TFC respectively for 24 h,while the dexrazoxane group was treated with 10 μmol/L dexrazoxane for the same period. Viability of myocardial cells was measured by CCK-8 kit. Apoptotic morphology was observed by fluorescent inverted microscope after Hoechst33258 staining. Mitochondrial transmembrane potential was determined by JC-1 kit. Expression levels of Bax,Bcl-2 and cleaved Caspase-3 were determined by Western blot. The concentration of SOD and MDA was assayed by colorimetric kit to investigate oxidative damage. Results: Compared with model group,viability of myocardial cells was significantly higher and the apoptosis was lower in TFC treament groups. Mitochondrion was also protected by TFC from the toxicity of epirubicin. The activity of SOD was enhanced,and the production of MDA was reduced significantly which treated by TFC( P < 0. 05),and the apoptosis was attenuated by causing higher expression of Bax,Bcl-2 and inhibited the production of cleaved Caspase-3 which treated with TFC. Conclusion: TFC can inhibit mitochondria-dependent apoptosis pathway via attenuating lipid peroxidation and thus mitigated cardiac toxicity of epirubicin.
Objective: To study the protective effect and mechanism of total flavones of Clematis filamentosa( TFC) mitigating cardiotoxicity which induced by epirubicin( Epi). Methods: The myocardial cells separated from neonate SD rats was induced to apoptosis with 1. 0 μmol/L epirubicin to establish cardiotoxicity model. Three experimental groups were treated with 25,50,100 μg/m L TFC respectively for 24 h,while the dexrazoxane group was treated with 10 μmol/L dexrazoxane for the same period. Viability of myocardial cells was measured by CCK-8 kit. Apoptotic morphology was observed by fluorescent inverted microscope after Hoechst33258 staining. Mitochondrial transmembrane potential was determined by JC-1 kit. Expression levels of Bax,Bcl-2 and cleaved Caspase-3 were determined by Western blot. The concentration of SOD and MDA was assayed by colorimetric kit to investigate oxidative damage. Results: Compared with model group,viability of myocardial cells was significantly higher and the apoptosis was lower in TFC treament groups. Mitochondrion was also protected by TFC from the toxicity of epirubicin. The activity of SOD was enhanced,and the production of MDA was reduced significantly which treated by TFC( P < 0. 05),and the apoptosis was attenuated by causing higher expression of Bax,Bcl-2 and inhibited the production of cleaved Caspase-3 which treated with TFC. Conclusion: TFC can inhibit mitochondria-dependent apoptosis pathway via attenuating lipid peroxidation and thus mitigated cardiac toxicity of epirubicin.
引文
[1]Koitabashi N,Ohyama Y,Tateno R,et al.Reversible Cardiomyopathy after epirubicin administration[J].Int Heart J,2015,56(4):466-468.
[2]Conway A,Mc Carthy AL,Lawrence P,et al.The prevention,detection and management of cancer treatment-induced cardiotoxicity:a meta-review[J].BMC Cancer,2015,7(15):366.
[3]Stěrba M,PopelováO,VávrováA,et al.Oxidative stress,redox signaling,and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection[J].Antioxid Redox Signal,2013,18(8):899-929.
[4]胡宗礼,黄晓萍,陈珺霞.甘木通抗心肌缺血的有效部位与作用研究[J].中国药学杂志,2011,49(9):668-670.
[5]聂阳,陈新颖,杨燕军.甘木通总黄酮抗心肌缺血的作用[J].中国实验方剂学志,2014,20(22):176-179.
[6]巫玮.药物/化合物多系统体外急性毒性初步评价模型的建立[D].广州:广东药学院,2009.
[7]聂阳,黄勇红,李博.表面活性剂-超声协同提取甘木通总黄酮工艺的研究[J].中成药,2013,35(9):2040-2042.
[8]王晓林,钟方丽,刘延超,等.大孔吸附树脂纯化东北铁线莲总黄酮的工艺研究[J].上海中医药杂志,2012,(4):80-85.
[9]高蒙蒙.红车轴草总黄酮对氧化应激诱导的血管内皮细胞和心肌细胞损伤的保护作用及机制研究[D].北京:北京协和医学院,2013.
[10]刘晓婷,王延让,张明.线粒体介导细胞凋亡的研究进展[J].环境与健康杂志,2013,30(2):182-185.
[11]刘铮,张元霞,周萍,李茜楠.线粒体膜通透性增加引起凋亡机制的研究进展[J].哈尔滨医科大学学报,2016,50(1):90-93.
[12]刘淑珍,尤鑫,熊小栓.心肌再灌注对抑郁大鼠心肌细胞凋亡以及bcl-2、bax和caspase-3表达的影响[J].中国病理生理杂志,2012,28(3):453-458.
[13]Raj S,Franco VI,Lipshultz SE.Anthracycline-induced cardiotoxicity:a review of pathophysiology,diagnosis,and treatment[J].Curr Treat Options Cardiovasc Med,2014,16(6):315.
[14]Seif AE,Walker DM,Li Y,et al.Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients[J].Pediatr Blood Cancer,2015,62(4):704-709.
[2]Conway A,Mc Carthy AL,Lawrence P,et al.The prevention,detection and management of cancer treatment-induced cardiotoxicity:a meta-review[J].BMC Cancer,2015,7(15):366.
[3]Stěrba M,PopelováO,VávrováA,et al.Oxidative stress,redox signaling,and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection[J].Antioxid Redox Signal,2013,18(8):899-929.
[4]胡宗礼,黄晓萍,陈珺霞.甘木通抗心肌缺血的有效部位与作用研究[J].中国药学杂志,2011,49(9):668-670.
[5]聂阳,陈新颖,杨燕军.甘木通总黄酮抗心肌缺血的作用[J].中国实验方剂学志,2014,20(22):176-179.
[6]巫玮.药物/化合物多系统体外急性毒性初步评价模型的建立[D].广州:广东药学院,2009.
[7]聂阳,黄勇红,李博.表面活性剂-超声协同提取甘木通总黄酮工艺的研究[J].中成药,2013,35(9):2040-2042.
[8]王晓林,钟方丽,刘延超,等.大孔吸附树脂纯化东北铁线莲总黄酮的工艺研究[J].上海中医药杂志,2012,(4):80-85.
[9]高蒙蒙.红车轴草总黄酮对氧化应激诱导的血管内皮细胞和心肌细胞损伤的保护作用及机制研究[D].北京:北京协和医学院,2013.
[10]刘晓婷,王延让,张明.线粒体介导细胞凋亡的研究进展[J].环境与健康杂志,2013,30(2):182-185.
[11]刘铮,张元霞,周萍,李茜楠.线粒体膜通透性增加引起凋亡机制的研究进展[J].哈尔滨医科大学学报,2016,50(1):90-93.
[12]刘淑珍,尤鑫,熊小栓.心肌再灌注对抑郁大鼠心肌细胞凋亡以及bcl-2、bax和caspase-3表达的影响[J].中国病理生理杂志,2012,28(3):453-458.
[13]Raj S,Franco VI,Lipshultz SE.Anthracycline-induced cardiotoxicity:a review of pathophysiology,diagnosis,and treatment[J].Curr Treat Options Cardiovasc Med,2014,16(6):315.
[14]Seif AE,Walker DM,Li Y,et al.Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients[J].Pediatr Blood Cancer,2015,62(4):704-709.